Exploring the Impact of Non-Ablative Erbium Laser Therapy on Recurrent Vaginal Candidiasis

To assess the effect of non-ablative Er:YAG laser therapy on the symptoms and microbiological conditions of women with recurrent vulvovaginal candidiasis (RVVC).

One hundred and sixty-seven women (mean age 34.1 ± 8.57 years) participated in this cohort study. Women diagnosed with RVVC received four vaginal laser therapies within 4 months. At baseline, 3 months, and 9 months after the last laser therapy microbiological assessment, improvement of five bothersome symptoms related to vaginal infection (burning, itching, dyspareunia, dysuria, and abnormal discharge), and the safety of the laser therapy and overall patient satisfaction were assessed.

Non-ablative vaginal Er:YAG laser therapy resulted in improvements of all bothersome symptoms and was statistically significant at 3 and 9 months following the therapy. A complete resolution in symptoms (VAS = 0) was observed in 38%-74% of women, depending on the symptom. Nine months after therapy, the prevalence of Candida albicans dropped from 80% to 30%, and a complete elimination of pathogens was detected in 64% of the women. The laser therapy appeared to be effective in the elimination of non-albicans Candida species. A total of 86% of the patients reported being satisfied or very satisfied with the therapy. Only minor and transient adverse effects were recorded during the study.

Non-ablative vaginal Er:YAG laser therapy proved to be a promising treatment for RVVC in women. The effect was achieved by improving their vaginal health by lowering the load of pathogenic yeast and by promoting the restoration of a favorable environment for normal microflora.